do i qualify for tirzepatide BMI Guidelines Eligibility bmi required for glp 1

Key information to disclose includes: Medication name and dose "I take Wegovy (semaglutide) 2.4 mg once weekly by subcutaneous injection" Duration of treatment how long you have been taking Wegovy and whether you are still in the dose-escalation phase Current side effects any ongoing nausea, vomiting, diarrhoea, dizziness, or other symptoms Reason for prescription whether prescribed for obesity alone or with comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease Overall health status current weight, blood pressure, and general wellbeing Donation staff will ask about your medical history and may need to consult with medical advisors regarding Wegovy

63 KennaH

Eliminating dietary fat entirely accelerates weight loss temporarily but increases complication risk significantly

Tirzepatide does not cause traditional withdrawal symptoms because it does not create physical dependence